Markets

Affimed Therapeutics prices IPO at $7, below the range

A generic image of a dollar bill on top of a chart
Credit: Shutterstock photo

Affimed Therapeutics, a biotech developing immunotherapies for lymphomas, leukemia and other cancers, raised $56 million by offering 8 million shares at $7, below the range of $11 to $13. Affimed Therapeutics plans to list on the NASDAQ under the symbol AFMD. Affimed Therapeutics initially filed confidentially on 5/23/2014. Jefferies & Co., Leerink Partners and BMO Capital Markets acted as lead managers on the deal.

The article Affimed Therapeutics prices IPO at $7, below the range originally appeared on IPO investment manager Renaissance Capital's web site renaissancecapital.com.

Investment Disclosure: The information and opinions expressed herein were prepared by Renaissance Capital's research analysts and do not constitute an offer to buy or sell any security. Renaissance Capital, the Renaissance IPO ETF (symbol: IPO) or the Global IPO Fund (symbol: IPOSX) , may have investments in securities of companies mentioned.

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.


The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

In This Story

AFMD

Other Topics

IPOs